Park Square has placed Richard Andrews as CEO of Azitra, Inc.
Azitra, Inc. today announced the appointment of Richard Andrews (Rick) as President and CEO. Azitra is focused on treating skin disease by combining the potential of the microbiome with state of the art molecular genetics. Mr. Andrews will work closely with Azitra's founding scientist, Travis Whitfill, who will now serve as Chief Scientific Officer. Rick Andrews brings more than 35 years of experience working with biotechnology companies from inception through successful clinical development, and most recently served as CEO of Thrasos Therapeutics. While at Thrasos, RenaMed and EcoScience, Mr. Andrews built strong operating teams and secured significant levels of research and development investment. Mr. Andrews was trained as a physical biochemist and chemical engineer at MIT, Purdue University and Hobart College. He currently serves on the Board of Directors of ProThera Biologics and Lucidicor Bio.
unknownx500
